The Medicine Matters oncology team welcomes comments from all users on any aspect of our website. However, please note that we cannot provide cancer information or guidance to patients or respond to any queries that are not directly related to our website.
Browse specialties
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs
ctDNA and bladder cancer: Current understanding and beyond
ROS1 fusion-positive NSCLC
NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC
Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy
ALK fusion-positive NSCLC: International approaches to management
RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC
COVID-19 & cancer
Conferences